← All trials
NCT02630095
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2015
- Primary completion
- Sep 1, 2018
- Completion date
- Sep 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 96
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Fudan UniversityLead sponsor
- Fudan UniversityReponsible party - principal investigator
- Fudan UniversityStudy director
- Eastern Hepatobiliary Surgery HospitalCollaborator
- Fudan UniversityCollaborator
- Shanghai University of Traditional Chinese MedicineCollaborator
- Ningxia Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.